Tracers / [111In]DO3A-BODIPY-Tz-TCO-trastuzumab
[111In]DO3A-BODIPY-Tz-TCO-trastuzumab
Also written as [In-111]In-DO3A-BODIPY-Tz-TCO-trastuzumab
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- DO3A-BODIPY-Tz conjugated to trastuzumab via TCO/tetrazine click chemistry, a multi-modal (fluorescent-chelator-antibody) HER2-targeted radioimmunoconjugate
- Target / mechanism
- HER2 (via trastuzumab conjugated through TCO/tetrazine IEDDA reaction) PMID 35666363
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | >99% | >99% | DO3A-BODIPY-Tz (13) | 35666363 2022 EJNMMI Radiopharm Chem Radiolabeling procedures followed closely those outline previously (Ramogida et al. 2015; Spreckelmeyer et al. 2017; Comba et al. 2017). — Radiochemical conversion yield (%RCC) was determined to be > 99% by iTLC-SG |
Need this precursor?We can point you to suppliers for [111In]DO3A-BODIPY-Tz-TCO-trastuzumab, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 35666363. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 35666363: 'DO3A-BODIPY-Tz (13)'. Stage set/updated at stage 23 from PMID 35666363: 'Pilot small animal in vivo immuno-SPECT imaging with [111In]In-DO3A-BODIPY-Tz-TCO-trastuzumab was also conducted and exhibited high tumor uptake (21.2 ± 5.6%ID/g 6 days post-injection) with low uptake in non-target tissues.'.